Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

Hims & Hers stirred the weight-loss waters by announcing it now offers prescriptions for Zepbound, Eli Lilly’s premium GLP-1 ...

The telehealth company Hims & Hers Health is expanding its weight-loss offerings by adding new medications to its platform.

Primary care company knownwell said on Wednesday it will provide health and weight-management services on Eli Lilly's ...

The telehealth company is offering Lilly’s branded form of tirzepatide—approved for weight loss—on its site for $1,899 a ...

Eli Lilly quickly disassociated itself from Hims & Hers after the telehealth company said it was selling the pharmaceutical ...

The FDA's new rule restricting the sale of compounded semaglutide could make it more difficult for some people to obtain ...

Meanwhile, the first major obesity-related phase 3 trial for orforglipron is set to complete in July. If the data from the ...

Viking Therapeutics (NASDAQ: VKTX) is operating in one of the highest-growth pharma areas around. Viking doesn't sell weight ...

Eli Lilly has launched legal attacks on two compounding pharmacies, accusing them of churning out unapproved Zepbound ...

Europe’s pharmaceutical sector is bracing for the potential impact of U.S. tariffs as hopes of an industry-wide exemption by ...